In Part 1 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains what doctors look for and ask about when diagnosing lung cancer, and how you can be sure you received the correct diagnosis.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.

[powerpress]

Admit it. You have probably wondered why you or your loved one was unlucky enough to get lung cancer while that obnoxious neighbor or coworker has smoked 2 packs a day for 50 years and doesn’t even have a cough. In fact, only about 15% of male smokers and 10% of female smokers eventually develop lung cancer. The field at large has been searching for why some smokers get lung cancer and others don’t for many years, and while progress has been made the answer has been elusive.

Erlotinib (Tarceva) was approved for treatment of progressive non-small cell lung cancer (NSCLC) after the BR21 study that showed that tarceva not only improved survival but also improved lung cancer symptoms and quality of life. This study and others have also taught us that the benefit of tarceva is much better in those who had never smoked and less effective in current smokers.